Literature DB >> 9553725

Mitochondrial permeability transition in apoptosis and necrosis.

T Hirsch1, S A Susin, I Marzo, P Marchetti, N Zamzami, G Kroemer.   

Abstract

Apoptosis has classically been viewed as a process not involving mitochondria, whereas the implication of mitochondrial dysfunction in necrosis has been recognized for several decades. Recently, it has become clear that apoptosis implies a disruption of mitochondrial membrane intregrity that is decisive for the cell death process. Cytofluorometric methods assessing the mitochondrial membrane function and structure can be employed to demonstrate that, at least in most models of apoptosis, mitochondrial changes precede caspase and nuclease activation. Moreover, pharmacological and genetic experiments suggest that the loss of mitochondrial membrane integrity is a critical event of the apoptotic process, beyond or at the point of no return of programmed cell death. Inhibitors of the mitochondrial megachannel (= permeability transition pore) can prevent both the mitochondrial and the post-mitochondrial manifestations of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553725     DOI: 10.1023/a:1007486022411

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  31 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Mitochondria and apoptosis: HQ or high-security prison?

Authors:  N J Waterhouse; D R Green
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

3.  Dual responses of CNS mitochondria to elevated calcium.

Authors:  N Brustovetsky; J M Dubinsky
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 4.  Apoptosis-detecting radioligands: current state of the art and future perspectives.

Authors:  Christophe M M Lahorte; Jean-Luc Vanderheyden; Neil Steinmetz; Christophe Van de Wiele; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-12       Impact factor: 9.236

5.  Selective Aryl Hydrocarbon Receptor Modulator 3,3'-Diindolylmethane Impairs AhR and ARNT Signaling and Protects Mouse Neuronal Cells Against Hypoxia.

Authors:  J Rzemieniec; E Litwa; A Wnuk; W Lason; W Krzeptowski; M Kajta
Journal:  Mol Neurobiol       Date:  2015-10-17       Impact factor: 5.590

6.  The cyclosporine-A-sensitive mitochondrial permeability transition pore in winter wheat at a low temperature and under oxidative stress.

Authors:  N S Pavlovskaya; O V Savinova; O I Grabel'nykh; T P Pobezhimova; N A Koroleva; V K Voinikov
Journal:  Dokl Biol Sci       Date:  2007 Nov-Dec

Review 7.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 8.  Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.

Authors:  Dmitry B Zorov; Magdalena Juhaszova; Steven J Sollott
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

9.  Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells.

Authors:  A C Okaro; D A Fennell; M Corbo; B R Davidson; F E Cotter
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

Authors:  Natalie E Scholpa; Hannah Williams; Wenxue Wang; Daniel Corum; Aarti Narang; Stephen Tomlinson; Patrick G Sullivan; Alexander G Rabchevsky; Rick G Schnellmann
Journal:  J Neurotrauma       Date:  2018-11-16       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.